Kyntra BIO, Inc. (KYNB) intrinsic value & 10-year financials
Kyntra BIO, Inc. (KYNB) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 31.1% a year to $6.4M, with an average return on invested capital of -194.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.85
- Market cap
- $19.6M
- Revenue (FY2025)
- $6.4M
- Revenue growth (10-yr CAGR)
- -31.1%
- ROIC (10-yr avg)
- -194.4%
- Free cash flow (FY2025)
- -$4.8M
KYNB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $6.4M | $183.5M | $45.37 | -$4.8M | -712.7% | 16.6% |
| FY2024 | $29.6M | -$47.6M | -$0.48 | -$138.3M | -507.8% | 56.7% |
| FY2023 | $147.8M | -$284.2M | -$2.92 | -$317.5M | -190.7% | 161.7% |
| FY2022 | $140.7M | -$293.7M | -$3.14 | -$149.7M | -213.9% | -2055.8% |
| FY2021 | $235.3M | -$290.0M | -$3.14 | -$87.4M | -122.6% | 558.8% |
| FY2020 | $176.3M | -$189.3M | -$2.11 | $77.6M | -108.8% | -193.4% |
| FY2019 | $256.6M | -$77.0M | — | -$84.5M | -34.8% | -18.9% |
| FY2018 | $213.0M | -$86.4M | — | -$84.2M | -40.7% | -34.4% |
| FY2017 | $131.0M | -$126.2M | — | -$75.0M | -93.6% | -367.7% |
| FY2016 | $183.2M | -$61.7M | — | $5.9M | -29.3% | -67.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
KYNTRA BIO, INC. is facing top-line stagnation, with revenue contracting over the decade.
KYNTRA BIO, INC. has historically struggled to out-earn its cost of capital, averaging just -6.6% ROIC.
KYNTRA BIO, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, KYNTRA BIO, INC. is modeled at -31.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2098.83 per share.